Global Animal Vaccine Market 2025-2035
Description
Global Animal Vaccine Market Size, Share & Trends Analysis by Type (Porcine Vaccines, Poultry Vaccines, Livestock Vaccines, Aquaculture Vaccines, Companion Animal Vaccines, and Other Animal Vaccines), and by Technology (Live Attenuated Vaccines, Killed/Inactivated Vaccine, Recombinant Vaccines, and Other) Forecast Period (2025-2035)
Industry Overview
Animal vaccine market was valued at $13.5 billion in 2024 and is projected to reach $38.7 billion by 2035, growing at a CAGR of 10.1% during the forecast period (2025-2035). The market is growing due to factors like the increasing prevalence of zoonotic and infectious diseases, rising global demand for animal protein, and the growing number of pet owners. Technological advancements in vaccine development and a greater focus on animal health awareness are also significant drivers. Key restraints include the high cost and long timelines for vaccine development and regulatory approval, and potential adverse effects on animal health.
Market Dynamics
Rising Demand For Protein And Intensification Of Livestock Production
Growing global demand for animal-source protein (poultry, pork, beef) drives herd/flock intensification and increased animal movements conditions that raise infectious-disease risk and the need for preventive vaccination programs. Governments and integrators invest in vaccination as a cost-effective method to secure production, reduce mortality, and stabilize supply chains, particularly in Asia-Pacific and Latin America where production is expanding fastest.
Zoonotic-Disease Awareness, Regulatory Pressure And Public-Health Linkage
High-profile outbreaks (avian influenza, foot-and-mouth disease, and other zoonoses) and tighter biosecurity/regulatory measures have encouraged prophylactic vaccination and national immunization campaigns. Public-health agencies and trade regulators increasingly view animal vaccination as integral to One Health strategies and food-safety policy, prompting government tenders and emergency procurement that lift short-term demand and spur longer-term programmatic funding. Recent national campaigns and tenders illustrate how outbreak responses translate directly into market spikes for vaccine manufacturers.
Technological Innovation And Supply-Chain Improvements
Advances in recombinant and vectored vaccine platforms, improved adjuvants, and thermostable formulations (reducing cold-chain dependency) expand usable vaccine portfolios for species and geographies previously hard to reach. Meanwhile, investments in local manufacturing, fill-finish capacity and cold-chain logistics lower distribution barriers in emerging markets. These technology and infrastructure improvements both raise marketable addressable demand and enable premium pricing for differentiated vaccines.
Market Segmentation
The Among all the segments, the livestock vaccines segment is expected to lead the global animal vaccine market during the forecast period. This dominance is primarily attributed to the increasing global demand for meat, milk, and other animal-based products, which has significantly expanded livestock farming across both developed and emerging economies. Rising incidences of infectious diseases such as foot-and-mouth disease (FMD), bovine respiratory disease (BRD), and lumpy skin disease in cattle and swine populations have prompted governments and farmers to adopt preventive vaccination programs on a large scale. Moreover, major animal health companies are increasingly investing in research and development of next-generation vaccines tailored for livestock health management, including combination and recombinant vaccines offering broader immunity coverage.
The presence of strong veterinary healthcare infrastructure in key markets such as the US, China, India, and Brazil, along with large-scale government immunization drives for cattle and swine, further supports the growth of this segment. In addition, improved cold-chain logistics and the availability of cost-effective vaccine formulations in developing regions are making livestock vaccination more accessible and sustainable, thereby consolidating the segment’s leadership position in the global market.
Recombinant Vaccines: The Fastest-Growing Segment
The recombinant vaccines segment is the fastest-growing area in the global animal vaccine market, propelled by a combination of scientific, economic, and regulatory factors. Advances in recombinant DNA technology, viral vectors, and subunit platforms are enabling vaccines with enhanced safety, higher antigen specificity, and the ability to differentiate infected from vaccinated animals (DIVA). This DIVA feature is crucial for trade-sensitive livestock diseases, prompting governments and large integrators to adopt these solutions for both national programs and commercial herds.
At the same time, recombinant vaccine technologies support rapid development and scalable manufacturing, appealing to both multinational animal-health firms and regional biotech companies eager to serve the growing demand in emerging markets particularly where poultry and swine production are intensifying. The premium pricing of these technologically advanced vaccines sustains R&D investments and encourages manufacturers to expand fill-and-finish facilities and cold-chain capacity, further improving global market access.
Additionally, the rise in companion-animal ownership and consumers’ willingness to invest in advanced prophylactic and oncology-adjacent vaccines are expanding the high-value segment. Meanwhile, regulators in developed markets, favoring safer and well-characterized biologics, are streamlining approvals for validated recombinant platforms, shortening time-to-market.
Regional Outlook
The global animal vaccine market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US dominates the global animal vaccine market, holding a major share due to its well-established veterinary healthcare infrastructure, strong regulatory frameworks, and high awareness regarding animal disease prevention and zoonotic risks. The country’s extensive livestock population-particularly cattle, poultry, and swine-along with rising pet ownership rates and growing expenditure on companion animal healthcare, has significantly contributed to vaccine demand. The U.S. benefits from advanced R&D capabilities supported by leading pharmaceutical and biotech companies such as Zoetis, Merck Animal Health, and Elanco, which maintain extensive product portfolios covering both livestock and companion animal segments. Continuous government initiatives from agencies like the USDA and CDC to control outbreaks such as avian influenza, rabies, and foot-and-mouth disease further strengthen vaccine adoption rates.
In addition, the strong presence of academic research institutions and collaborations between private manufacturers and federal agencies enable faster innovation and approval of next-generation recombinant and DNA-based vaccines. Robust cold-chain distribution networks and digital supply-chain management systems ensure efficient vaccine delivery across diverse geographical regions, reducing wastage and improving accessibility. The country’s focus on biosafety and One Health initiatives, which integrate human, animal, and environmental health policies, additionally plays a crucial role in sustaining market leadership. With rising investments in precision livestock farming and disease surveillance technologies, the U.S. continues to set the benchmark for animal health management, positioning itself as the leading hub for animal vaccine production, innovation, and global export.
Market Players Outlook
The major companies operating in the global animal vaccine market include Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco Animal Health Inc., Merck Animal Health, and Zoetis Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
Industry Overview
Animal vaccine market was valued at $13.5 billion in 2024 and is projected to reach $38.7 billion by 2035, growing at a CAGR of 10.1% during the forecast period (2025-2035). The market is growing due to factors like the increasing prevalence of zoonotic and infectious diseases, rising global demand for animal protein, and the growing number of pet owners. Technological advancements in vaccine development and a greater focus on animal health awareness are also significant drivers. Key restraints include the high cost and long timelines for vaccine development and regulatory approval, and potential adverse effects on animal health.
Market Dynamics
Rising Demand For Protein And Intensification Of Livestock Production
Growing global demand for animal-source protein (poultry, pork, beef) drives herd/flock intensification and increased animal movements conditions that raise infectious-disease risk and the need for preventive vaccination programs. Governments and integrators invest in vaccination as a cost-effective method to secure production, reduce mortality, and stabilize supply chains, particularly in Asia-Pacific and Latin America where production is expanding fastest.
Zoonotic-Disease Awareness, Regulatory Pressure And Public-Health Linkage
High-profile outbreaks (avian influenza, foot-and-mouth disease, and other zoonoses) and tighter biosecurity/regulatory measures have encouraged prophylactic vaccination and national immunization campaigns. Public-health agencies and trade regulators increasingly view animal vaccination as integral to One Health strategies and food-safety policy, prompting government tenders and emergency procurement that lift short-term demand and spur longer-term programmatic funding. Recent national campaigns and tenders illustrate how outbreak responses translate directly into market spikes for vaccine manufacturers.
Technological Innovation And Supply-Chain Improvements
Advances in recombinant and vectored vaccine platforms, improved adjuvants, and thermostable formulations (reducing cold-chain dependency) expand usable vaccine portfolios for species and geographies previously hard to reach. Meanwhile, investments in local manufacturing, fill-finish capacity and cold-chain logistics lower distribution barriers in emerging markets. These technology and infrastructure improvements both raise marketable addressable demand and enable premium pricing for differentiated vaccines.
Market Segmentation
- Based on the type, the market is segmented into porcine vaccines, poultry vaccines, livestock vaccines, aquaculture vaccines, companion animal vaccines, and other animal vaccines.
- Based on the technology, the market is segmented into live attenuated vaccines, killed/inactivated vaccine, recombinant vaccines, and other.
The Among all the segments, the livestock vaccines segment is expected to lead the global animal vaccine market during the forecast period. This dominance is primarily attributed to the increasing global demand for meat, milk, and other animal-based products, which has significantly expanded livestock farming across both developed and emerging economies. Rising incidences of infectious diseases such as foot-and-mouth disease (FMD), bovine respiratory disease (BRD), and lumpy skin disease in cattle and swine populations have prompted governments and farmers to adopt preventive vaccination programs on a large scale. Moreover, major animal health companies are increasingly investing in research and development of next-generation vaccines tailored for livestock health management, including combination and recombinant vaccines offering broader immunity coverage.
The presence of strong veterinary healthcare infrastructure in key markets such as the US, China, India, and Brazil, along with large-scale government immunization drives for cattle and swine, further supports the growth of this segment. In addition, improved cold-chain logistics and the availability of cost-effective vaccine formulations in developing regions are making livestock vaccination more accessible and sustainable, thereby consolidating the segment’s leadership position in the global market.
Recombinant Vaccines: The Fastest-Growing Segment
The recombinant vaccines segment is the fastest-growing area in the global animal vaccine market, propelled by a combination of scientific, economic, and regulatory factors. Advances in recombinant DNA technology, viral vectors, and subunit platforms are enabling vaccines with enhanced safety, higher antigen specificity, and the ability to differentiate infected from vaccinated animals (DIVA). This DIVA feature is crucial for trade-sensitive livestock diseases, prompting governments and large integrators to adopt these solutions for both national programs and commercial herds.
At the same time, recombinant vaccine technologies support rapid development and scalable manufacturing, appealing to both multinational animal-health firms and regional biotech companies eager to serve the growing demand in emerging markets particularly where poultry and swine production are intensifying. The premium pricing of these technologically advanced vaccines sustains R&D investments and encourages manufacturers to expand fill-and-finish facilities and cold-chain capacity, further improving global market access.
Additionally, the rise in companion-animal ownership and consumers’ willingness to invest in advanced prophylactic and oncology-adjacent vaccines are expanding the high-value segment. Meanwhile, regulators in developed markets, favoring safer and well-characterized biologics, are streamlining approvals for validated recombinant platforms, shortening time-to-market.
Regional Outlook
The global animal vaccine market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US dominates the global animal vaccine market, holding a major share due to its well-established veterinary healthcare infrastructure, strong regulatory frameworks, and high awareness regarding animal disease prevention and zoonotic risks. The country’s extensive livestock population-particularly cattle, poultry, and swine-along with rising pet ownership rates and growing expenditure on companion animal healthcare, has significantly contributed to vaccine demand. The U.S. benefits from advanced R&D capabilities supported by leading pharmaceutical and biotech companies such as Zoetis, Merck Animal Health, and Elanco, which maintain extensive product portfolios covering both livestock and companion animal segments. Continuous government initiatives from agencies like the USDA and CDC to control outbreaks such as avian influenza, rabies, and foot-and-mouth disease further strengthen vaccine adoption rates.
In addition, the strong presence of academic research institutions and collaborations between private manufacturers and federal agencies enable faster innovation and approval of next-generation recombinant and DNA-based vaccines. Robust cold-chain distribution networks and digital supply-chain management systems ensure efficient vaccine delivery across diverse geographical regions, reducing wastage and improving accessibility. The country’s focus on biosafety and One Health initiatives, which integrate human, animal, and environmental health policies, additionally plays a crucial role in sustaining market leadership. With rising investments in precision livestock farming and disease surveillance technologies, the U.S. continues to set the benchmark for animal health management, positioning itself as the leading hub for animal vaccine production, innovation, and global export.
Market Players Outlook
The major companies operating in the global animal vaccine market include Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco Animal Health Inc., Merck Animal Health, and Zoetis Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
- In June 2025, Boehringer Ingelheim launched a single-dose, next-generation poultry vaccine in India, providing protection against Bursal, Newcastle, and Marek's disease. The vaccine addresses practical challenges faced by Indian poultry farmers, offering early, reliable, and long-lasting immunity with just one administration at the hatchery. It reduces the need for multiple field vaccinations, lowers labor requirements, and minimizes bird handling stress.
- In June 2024, USDA approves Merck Animal Health's NOBIVAC NXT Canine Flu H3N2, the first and only RNA-particle technology vaccine for canine influenza. The vaccine, developed by Merck Animal Health, uses RNA-particle technology to provide a precise immune response against viral and bacterial pathogens, expected to be available in veterinary clinics and hospitals.
- Market value data analysis for 2024 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global animal vaccine market. Based on the availability of data, information related to new products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
Table of Contents
189 Pages
- 1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Animal Vaccine Market Sales Analysis - Type | Technology ($ Million)
- Animal Vaccine Market Sales Performance of Top Countries
- 1.1. Research Methodology
- Primary Research Approach
- Secondary Research Approach
- 1.2. Market Snapshot
- 2. Market Overview and Insights
- 2.1. Scope of the Study
- 2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Animal Vaccine Market Trends
- 2.2.2. Market Recommendations
- 2.3. Porter's Five Forces Analysis for the Animal Vaccine Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes
- 3. Market Determinants
- 3.1. Market Drivers
- 3.1.1. Drivers For Global Animal Vaccine Market: Impact Analysis
- 3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Animal Vaccine Market: Impact Analysis
- 3.3. Market Opportunities
- 3.3.1. Opportunities For Global Animal Vaccine Market: Impact Analysis
- 4. Competitive Landscape
- 4.1. Competitive Dashboard - Animal Vaccine Market Revenue and Share by Manufacturers
- Animal Vaccine Product Comparison Analysis
- Top Market Player Ranking Matrix
- 4.2. Key Company Analysis
- 4.2.1. Boehringer Ingelheim International GmbH
- 4.2.1.1. Overview
- 4.2.1.2. Product Portfolio
- 4.2.1.3. Financial Analysis
- 4.2.1.4. SWOT Analysis
- 4.2.1.5. Business Strategy
- 4.2.2. Ceva Santé Animale
- 4.2.2.1. Overview
- 4.2.2.2. Product Portfolio
- 4.2.2.3. Financial Analysis
- 4.2.2.4. SWOT Analysis
- 4.2.2.5. Business Strategy
- 4.2.3. Elanco Animal Health Inc.
- 4.2.3.1. Overview
- 4.2.3.2. Product Portfolio
- 4.2.3.3. Financial Analysis
- 4.2.3.4. SWOT Analysis
- 4.2.3.5. Business Strategy
- 4.2.4. Merck Animal Health
- 4.2.4.1. Overview
- 4.2.4.2. Product Portfolio
- 4.2.4.3. Financial Analysis
- 4.2.4.4. SWOT Analysis
- 4.2.4.5. Business Strategy
- 4.2.5. Zoetis Inc.
- 4.2.5.1. Overview
- 4.2.5.2. Product Portfolio
- 4.2.5.3. Financial Analysis
- 4.2.5.4. SWOT Analysis
- 4.2.5.5. Business Strategy
- 4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration
- 5. Global Animal Vaccine Market Sales Analysis by Type ($ Million)
- 5.1. Porcine Vaccines
- 5.2. Poultry Vaccines
- 5.3. Livestock Vaccines
- 5.4. Aquaculture Vaccines
- 5.5. Companion Animal Vaccines
- 5.6. Other Animal Vaccines
- 6. Global Animal Vaccine Market Sales Analysis by Technology ($ Million)
- 6.1. Live Attenuated Vaccines
- 6.2. Killed/Inactivated Vaccine
- 6.3. Recombinant Vaccines
- 6.4. Other
- 7. Regional Analysis
- 7.1. North American Animal Vaccine Market Sales Analysis - Type | Technology ($ Million)
- Macroeconomic Factors for North America
- 7.1.1. United States
- 7.1.2. Canada
- 7.2. European Animal Vaccine Market Sales Analysis - Type | Technology ($ Million)
- Macroeconomic Factors for Europe
- 7.2.1. UK
- 7.2.2. Germany
- 7.2.3. Italy
- 7.2.4. Spain
- 7.2.5. France
- 7.2.6. Russia
- 7.2.7. Rest of Europe
- 7.3. Asia-Pacific Animal Vaccine Market Sales Analysis - Type | Technology ($ Million)
- Macroeconomic Factors for Asia-Pacific
- 7.3.1. China
- 7.3.2. Japan
- 7.3.3. South Korea
- 7.3.4. India
- 7.3.5. Australia & New Zealand
- 7.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 7.3.7. Rest of Asia-Pacific
- 7.4. Rest of the World Animal Vaccine Market Sales Analysis - Type | Technology ($ Million)
- Macroeconomic Factors for the Rest of the World
- 7.4.1. Latin America
- 7.4.2. Middle East and Africa
- 8. Company Profiles
- 8.1. Bavarian Nordic
- 8.1.1. Quick Facts
- 8.1.2. Company Overview
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategies
- 8.2. Bayer Animal
- 8.2.1. Quick Facts
- 8.2.2. Company Overview
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategies
- 8.3. Biogénesis Bagó
- 8.3.1. Quick Facts
- 8.3.2. Company Overview
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategies
- 8.4. Boehringer Ingelheim
- 8.4.1. Quick Facts
- 8.4.2. Company Overview
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategies
- 8.5. Boehringer Ingelheim Animal
- 8.5.1. Quick Facts
- 8.5.2. Company Overview
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategies
- 8.6. Cadila / Zydus Animal Health
- 8.6.1. Quick Facts
- 8.6.2. Company Overview
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategies
- 8.7. Cargill Animal Nutrition / Cargill
- 8.7.1. Quick Facts
- 8.7.2. Company Overview
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategies
- 8.8. Century/ONGC/Regional players
- 8.8.1. Quick Facts
- 8.8.2. Company Overview
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategies
- 8.9. Ceva Santé Animale
- 8.9.1. Quick Facts
- 8.9.2. Company Overview
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategies
- 8.10. Elanco Animal Health
- 8.10.1. Quick Facts
- 8.10.2. Company Overview
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategies
- 8.11. Hester Biosciences
- 8.11.1. Quick Facts
- 8.11.2. Company Overview
- 8.11.3. Product Portfolio
- 8.11.4. Business Strategies
- 8.12. HIPRA
- 8.12.1. Quick Facts
- 8.12.2. Company Overview
- 8.12.3. Product Portfolio
- 8.12.4. Business Strategies
- 8.13. IDEXX Laboratories
- 8.13.1. Quick Facts
- 8.13.2. Company Overview
- 8.13.3. Product Portfolio
- 8.13.4. Business Strategies
- 8.14. IDT Biologika
- 8.14.1. Quick Facts
- 8.14.2. Company Overview
- 8.14.3. Product Portfolio
- 8.14.4. Business Strategies
- 8.15. Kemin Industries
- 8.15.1. Quick Facts
- 8.15.2. Company Overview
- 8.15.3. Product Portfolio
- 8.15.4. Business Strategies
- 8.16. Kyoritsu Seiyaku
- 8.16.1. Quick Facts
- 8.16.2. Company Overview
- 8.16.3. Product Portfolio
- 8.16.4. Business Strategies
- 8.17. Merck / MSD Animal Health
- 8.17.1. Quick Facts
- 8.17.2. Company Overview
- 8.17.3. Product Portfolio
- 8.17.4. Business Strategies
- 8.18. Neogen Corp.
- 8.18.1. Quick Facts
- 8.18.2. Company Overview
- 8.18.3. Product Portfolio
- 8.18.4. Business Strategies
- 8.19. Phibro
- 8.19.1. Quick Facts
- 8.19.2. Company Overview
- 8.19.3. Product Portfolio
- 8.19.4. Business Strategies
- 8.20. Phibro Animal Health Corp.
- 8.20.1. Quick Facts
- 8.20.2. Company Overview
- 8.20.3. Product Portfolio
- 8.20.4. Business Strategies
- 8.21. Tianjin Ringpu Biotechnology
- 8.21.1. Quick Facts
- 8.21.2. Company Overview
- 8.21.3. Product Portfolio
- 8.21.4. Business Strategies
- 8.22. Vetoquinol
- 8.22.1. Quick Facts
- 8.22.2. Company Overview
- 8.22.3. Product Portfolio
- 8.22.4. Business Strategies
- 8.23. Virbac Group
- 8.23.1. Quick Facts
- 8.23.2. Company Overview
- 8.23.3. Product Portfolio
- 8.23.4. Business Strategies
- 8.24. Zoetis (USA)
- 8.24.1. Quick Facts
- 8.24.2. Company Overview
- 8.24.3. Product Portfolio
- 8.24.4. Business Strategies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
